Zai Lab Ltd (ZLAB) - Net Assets
Based on the latest financial reports, Zai Lab Ltd (ZLAB) has net assets worth $661.98 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.10 Billion) and total liabilities ($433.76 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible equity quality of Zai Lab Ltd to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $661.98 Million |
| % of Total Assets | 60.41% |
| Annual Growth Rate | N/A |
| 5-Year Change | -48.15% |
| 10-Year Change | N/A |
| Growth Volatility | 100.18 |
Zai Lab Ltd - Net Assets Trend (2015–2025)
This chart illustrates how Zai Lab Ltd's net assets have evolved over time, based on quarterly financial data. See Zai Lab Ltd liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Zai Lab Ltd (2015–2025)
The table below shows the annual net assets of Zai Lab Ltd from 2015 to 2025. For live valuation and market cap data, see Zai Lab Ltd (ZLAB) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $715.50 Million | -14.91% |
| 2024-12-31 | $840.90 Million | +5.62% |
| 2023-12-31 | $796.12 Million | -23.86% |
| 2022-12-31 | $1.05 Billion | -24.23% |
| 2021-12-31 | $1.38 Billion | +18.01% |
| 2020-12-31 | $1.17 Billion | +296.85% |
| 2019-12-31 | $294.66 Million | +17.36% |
| 2018-12-31 | $251.08 Million | +6.77% |
| 2017-12-31 | $235.17 Million | +556.18% |
| 2016-12-31 | $-51.55 Million | -180.63% |
| 2015-12-31 | $-18.37 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Zai Lab Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 260596477500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $7.00K | 0.00% |
| Other Comprehensive Income | $29.70 Million | 4.15% |
| Other Components | $3.31 Billion | 463.23% |
| Total Equity | $715.50 Million | 100.00% |
Zai Lab Ltd Competitors by Market Cap
The table below lists competitors of Zai Lab Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Progyny Inc
NASDAQ:PGNY
|
$2.01 Billion |
|
Dentsply Sirona Inc
NASDAQ:XRAY
|
$2.01 Billion |
|
Electricity Generating Public Company Limited
BK:EGCO
|
$2.01 Billion |
|
Lizhong Sitong Light Alloys Group Co Ltd
SHE:300428
|
$2.01 Billion |
|
MNC Studios International Tbk PT
JK:MSIN
|
$2.01 Billion |
|
Cisarua Mountain Dairy Tbk PT
JK:CMRY
|
$2.01 Billion |
|
Atlas Energy Solutions Inc.
NYSE:AESI
|
$2.01 Billion |
|
Kyland Technology Co Ltd
SHE:300353
|
$2.01 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zai Lab Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 840,898,000 to 715,500,000, a change of -125,398,000 (-14.9%).
- Net loss of 175,537,000 reduced equity.
- Other comprehensive income decreased equity by 20,818,000.
- Other factors increased equity by 70,957,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-175.54 Million | -24.53% |
| Other Comprehensive Income | $-20.82 Million | -2.91% |
| Other Changes | $70.96 Million | +9.92% |
| Total Change | $- | -14.91% |
Book Value vs Market Value Analysis
This analysis compares Zai Lab Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.74x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $-21.13 | $17.88 | x |
| 2016-12-31 | $-54.62 | $17.88 | x |
| 2017-12-31 | $10.81 | $17.88 | x |
| 2018-12-31 | $4.77 | $17.88 | x |
| 2019-12-31 | $4.58 | $17.88 | x |
| 2020-12-31 | $15.06 | $17.88 | x |
| 2021-12-31 | $14.84 | $17.88 | x |
| 2022-12-31 | $10.91 | $17.88 | x |
| 2023-12-31 | $8.24 | $17.88 | x |
| 2024-12-31 | $8.50 | $17.88 | x |
| 2025-12-31 | $6.53 | $17.88 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zai Lab Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -24.53%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -38.15%
- • Asset Turnover: 0.39x
- • Equity Multiplier: 1.64x
- Recent ROE (-24.53%) is above the historical average (-32.06%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-16.18 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-32.36 Million |
| 2017 | -21.42% | 0.00% | 0.00x | 1.06x | $-73.90 Million |
| 2018 | -55.39% | -107433.56% | 0.00x | 1.20x | $-164.18 Million |
| 2019 | -62.23% | -1412.16% | 0.04x | 1.21x | $-212.83 Million |
| 2020 | -23.00% | -549.26% | 0.04x | 1.11x | $-385.84 Million |
| 2021 | -51.05% | -488.16% | 0.09x | 1.17x | $-842.47 Million |
| 2022 | -42.40% | -206.14% | 0.18x | 1.17x | $-547.85 Million |
| 2023 | -42.03% | -125.46% | 0.26x | 1.30x | $-414.23 Million |
| 2024 | -30.57% | -64.44% | 0.34x | 1.41x | $-341.19 Million |
| 2025 | -24.53% | -38.15% | 0.39x | 1.64x | $-247.09 Million |
Industry Comparison
This section compares Zai Lab Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $661.98 Million | 0.00% | 0.66x | $2.01 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Zai Lab Ltd
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for … Read more